On June 30, 2020 Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, reported that it had completed a Series E Convertible Preferred Stock Offering in the amount of $1.5 Million (Press release, Guided Therapeutics, JUN 30, 2020, View Source [SID1234561587]). The financing was led by Rosalind Advisors, Inc. and Fieldhouse Capital Management, Inc. (FCMI), and included a combination of current and new institutional and qualified individual investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Funds will be used for the U.S. FDA clinical study and approval process, establishing the groundwork for listing on a U.S. national stock exchange, increasing international sales of its products and general corporate business. As reported previously, the Company has reached preliminary agreement with the U.S. FDA regarding its clinical plan and expects to begin its confirmatory study next quarter. In parallel, the Chinese FDA has begun its review of the Company’s LuViva Advanced Cervical Scan and approval in China is expected next year. The Company has applied to uplist from the OTC Pink sheets to the Bulletin Board and expects approval within the next 30 days.